Skip to content
Original
mp.weixin.qq.com·· 2 days agoScore78

Three CLDN18.2 ADCs Compete in Gastric Cancer as AstraZeneca and Innovent Phase III Data Emerge

In brief

Among gastric cancer Phase III results for three CLDN18.2 ADCs, two candidates improved overall survival in later-line gastric cancer patients in randomized studies. AstraZeneca's candidate extended median overall survival in third-line gastric cancer from 5 months to 10 months.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Clinical readout#Oncology#ADCs & conjugates#AstraZeneca
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.